Liminatus Pharma, Inc. (LIMN)
LIMN moved a median of -0.49% 30 minutes after news, and -0.26% by the close. How LIMN actually reacts to news — the realized, point-in-time move the market made, measured across 76 labeled events over the last three years with zero look-ahead.
LIMN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.45% | 42% | 76 |
| 30-min | -0.49% | 40% | 76 |
| 60-min | -0.40% | 46% | 76 |
| to close | -0.26% | 49% | 76 |
| Middle 50% of LIMN reactions | -3.92% to +2.00% |
|---|---|
| Median reaction (30-min) | -0.49% |
| Measured reactions | 76 |
Half of all Liminatus Pharma, Inc. news events land between -3.92% and +2.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when LIMN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LIMN's baseline. Nothing else.
Recent LIMN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Liminatus Pharma, Inc. For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | -7.57% | |
| Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule | Press release | GlobeNewswire | +1.01% | -7.57% | |
| Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy | Press release | GlobeNewswire | -4.57% | -7.16% | |
| Form 8-K Liminatus Pharma, Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.90% | |
| Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock | Press release | GlobeNewswire | +0.00% | +0.90% | |
| Form 10-Q Liminatus Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.69% | +8.77% | |
| Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement | Press release | GlobeNewswire | +3.06% | +6.62% | |
| Form 8-K Liminatus Pharma, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +6.45% | -1.87% | |
| Form 8-K Liminatus Pharma, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -2.76% | |
| Form 8-K Liminatus Pharma, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | -4.37% | |
| Form DEF 14A Liminatus Pharma, Inc. For: Aug 03 | SEC filing · Form DEF | SEC EDGAR | -2.21% | -0.37% | |
| Form 8-K Liminatus Pharma, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -8.62% | -10.31% | |
| Form PRE 14A Liminatus Pharma, Inc. For: Jun 29 | SEC filing · Form PRE | SEC EDGAR | -2.52% | +3.47% | |
| Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline | Press release | GlobeNewswire | -0.10% | +17.14% | |
| Form S-1 Liminatus Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -0.59% | -5.76% | |
| Form D Liminatus Pharma, Inc. | SEC filing · Form D | SEC EDGAR | -2.34% | -1.90% | |
| Form 8-K Liminatus Pharma, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +1.90% | +4.28% | |
| Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds | Press release | GlobeNewswire | +4.58% | +0.73% | |
| Form 8-K Liminatus Pharma, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +2.27% | |
| Liminatus Pharma Announces Nasdaq Delisting Notification | Press release | GlobeNewswire | -4.75% | -6.51% | |
| Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline | Press release | GlobeNewswire | -0.45% | -20.23% | |
| Form 8-K Liminatus Pharma, Inc. For: May 17 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -20.23% | |
| Form 10-Q Liminatus Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.67% | +0.05% | |
| Form 10-K Liminatus Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -0.64% | |
| Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody | Press release | GlobeNewswire | +0.00% | -5.74% | |
| Form 8-K Liminatus Pharma, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | +6.79% | |
| Form 8-K Liminatus Pharma, Inc. For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -11.77% | |
| Form EFFECT Liminatus Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.89% | +1.15% | |
| Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering | Press release | GlobeNewswire | -3.89% | +1.15% | |
| Form S-1 Liminatus Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -2.77% | -44.19% | |
| Form 8-K Liminatus Pharma, Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -17.15% | -20.55% | |
| Form 8-K Liminatus Pharma, Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -6.49% | |
| Form 8-K Liminatus Pharma, Inc. For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +8.46% | |
| Form 10-Q Liminatus Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.91% | +4.90% | |
| Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation | Press release | GlobeNewswire | +1.18% | -4.08% | |
| Form 10-Q Liminatus Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.41% | -1.71% | |
| Form 8-K Liminatus Pharma, Inc. For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | -3.04% | -1.22% | |
| Form NT 10-Q Liminatus Pharma, Inc. For: Jun 30 | SEC filing · Form NT | SEC EDGAR | -7.19% | -4.08% | |
| Form 8-K Liminatus Pharma, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -7.19% | -4.08% | |
| Form EFFECT Liminatus Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.70% | +2.80% | |
| Form S-1/A Liminatus Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.74% | -0.86% | |
| Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | Press release | GlobeNewswire | -1.73% | +7.53% | |
| Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy | Press release | GlobeNewswire | -3.10% | +9.29% | |
| Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | Press release | GlobeNewswire | +10.84% | +1.05% | |
| Form 8-K Liminatus Pharma, Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +0.18% | |
| Form 8-K Liminatus Pharma, Inc. For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | +0.46% | -3.36% | |
| Form 8-K Liminatus Pharma, Inc. For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -4.04% | |
| Form 8-K Liminatus Pharma, Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -2.49% | +21.78% | |
| Form 8-K Liminatus Pharma, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +3.61% | +4.59% | |
| Form S-1 Liminatus Pharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.17% | -20.73% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LIMN section they belong to.
Where else LIMN is measured.
LIMN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Liminatus Pharma, Inc.'s median reaction calculated?
Every labeled LIMN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 76 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of LIMN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LIMN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.